30 computer-programmer-"the"-"FEMTO-ST"-"U"-"Prof"-"Durham-University" "https:" "UCL" Fellowship positions
Sort by
Refine Your Search
-
therapy projects focused on neurological and neuromuscular disorders, contributing to an extensive novel therapeutic programme for RFC1 CANVAS led by Professor Andrea Cortese. The post is available from 01
-
work on the genomics of epilepsy within a wider programme of translational research, including genomics and climate change, under the supervision of Professor Sanjay Sisodiya. You will oversee a team of
-
posts On-site nursery On-site gym Enhanced maternity, paternity and adoption pay Employee assistance programme: Staff Support Service Discounted medical insurance Visit https://www.ucl.ac.uk/work-at-ucl
-
neuroscience, cardiovascular neurophysiology, and neural computation. Researchers have access to state of the art facilities (https://www.ucl.ac.uk/science-technology-platforms/ ) and the department has close
-
neuroscience, cardiovascular neurophysiology, and neural computation. Researchers have access to state of the art facilities (https://www.ucl.ac.uk/science-technology-platforms/) and the department has close
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and